Seventure goes with its gut for funding focus
This article was originally published in Clinica
With a rapid increase of research into the human microbiome, Seventure continues to attract investors into its Health for Life Capital Fund. Since launching the fund in December 2013, Seventure has raised a total of €100m ($105m) to back microbiome-focused businesses in the pharmaceutical and nutrition sectors. The latest €25m tranche edges the French venture capitalist closer to its €120m target.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.